Using macrophages to improve treatment for soft tissue sarcomas
Official title: Targeting Macrophages to Treat Soft Tissue Sarcomas
Funded at Resolute Science, INC. · NIH-11129899 · Data updated 2026-11-12
This study is testing a new treatment for soft tissue sarcomas that uses special immune cells to deliver cancer-fighting medicine directly to the tumors, aiming to be more effective and cause fewer side effects for patients.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Resolute Science, INC. NIH-funded |
| Lab location | 1 site (Rancho Santa Fe, United States) |
| Project start | August 1, 2023 |
| Project end | February 28, 2026 |
| Funding year | 2025 |
| Award (this year) | $998,212 |
| NIH project number | 5R44CA285036-03 |
| Project ID | NIH-11129899 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with soft tissue sarcomas, particularly those who have not responded well to existing treatments.
✕Less likely to help
Patients with soft tissue sarcomas who are not eligible for treatment or those with other unrelated health conditions may not benefit from this research.
What this research studies
This research focuses on developing a new therapy for soft tissue sarcomas (STS) by utilizing tumor-associated macrophages (TAMs) to deliver anti-cancer agents directly to tumors. The approach aims to overcome the limitations of current treatments, which often do not differentiate between the various subtypes of STS. By targeting TAMs, the therapy seeks to effectively kill cancer cells while minimizing resistance and side effects. The lead therapeutic, RS-5, has shown promising results in preclinical models, indicating its potential effectiveness against different STS subtypes.
Why it matters
Potential benefit: If successful, this research could provide a more effective and less costly treatment option for patients with soft tissue sarcomas.
How similar studies have gone: Other research has shown promise in targeting macrophages for cancer treatment, suggesting that this approach could be a viable and innovative strategy.
Where this research is happening
-
Resolute Science, INC.
Rancho Santa Fe, United States Active
Researchers
- Principal investigator: Barnett, Faith H — Resolute Science, INC.
- Study coordinator: Barnett, Faith H
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.